Epigral Q1 FY27 Results: ₹709 Cr Revenue, PAT ₹99 Cr

Key takeaway from the June quarter update

Epigral Limited reported revenue growth for the quarter ended June 30, 2026 (Q1 FY27), alongside a profit figure near ₹99 crore and EBITDA margin close to 25%. The company’s update comes through its stock exchange filing under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors approved the unaudited results on July 27, 2026. The filing also notes that the statutory auditors, S R B C & CO LLP, issued a limited review report. The company said the results were prepared in accordance with Ind AS 34 “Interim Financial Reporting” under Section 133 of the Companies Act, 2013.

Revenue growth, volumes and realizations

In the press release narrative, Epigral said revenue from operations rose 15% year-on-year to ₹709 crore, supported by a 5% increase in sales volume and improved realizations. The same communication stated net profit after tax (PAT) increased 25% year-on-year to ₹99 crore. It added that the company maintained an EBITDA margin of 25%. The company also framed the performance in the context of macro volatility and geopolitical tensions affecting raw material prices.

What the unaudited financial statements show

Alongside the headline narrative, the detailed financial numbers in the filing show revenue from operations at ₹705.36 crore for the quarter ended June 30, 2026, compared with ₹606.54 crore in the year-ago quarter ended June 30, 2025. Total income (including other income) is shown at ₹709.46 crore for the June 2026 quarter. Standalone net profit after tax is reported at ₹99.18 crore for the quarter ended June 30, 2026, compared with ₹160.41 crore in the corresponding quarter ended June 30, 2025. Consolidated net profit is reported at ₹99.74 crore versus ₹160.69 crore in the year-ago period.

EBITDA and margins: steady near 25%, but lower YoY

The filing states EBITDA for the quarter at about ₹180 crore (reported as ₹1.8B) versus about ₹160 crore (₹1.6B) in the year-ago period. It also states EBITDA margin contracted to 25.39% from 27% year-on-year. Separately, the metrics snapshot in the provided data mentions EBITDA of ₹179 crore with an EBITDA margin of 25%. Taken together, the reported EBITDA level is broadly consistent with the margin staying near 25%, while the year-on-year comparison points to some margin compression from the previous year’s level.

Costs rose sharply, led by materials

A key driver highlighted in the statement is higher input costs. Total expenses increased to ₹576.28 crore from ₹508.06 crore in the corresponding period. The cost of materials consumed rose to ₹430.18 crore from ₹318.19 crore, with the filing attributing this to higher input costs in the Chloro Alkali & Derivatives segment. The company also flagged broader macroeconomic volatility and geopolitically influenced raw material pricing as a backdrop. These cost movements provide context for why margin and profit comparisons can look different across disclosures.

Tax swing explains much of the profit comparison

The filing shows profit before tax (PBT) rose 25% to ₹133.18 crore from ₹106.73 crore. However, the reported tax line changed materially between the two periods. Tax expense for the quarter was ₹34.00 crore, compared with a net tax credit of ₹53.68 crore in the year-ago quarter. The company explained that the prior year included a one-time deferred tax credit of ₹80.87 crore arising from the remeasurement of deferred tax liabilities after opting for the reduced tax rate under Section 115BAA of the Income-tax Act, 1961. EPS (basic) is reported at ₹22.99 versus ₹37.18, reflecting the year-on-year decline in reported standalone PAT.

Leverage and return ratios cited in the quarter

The provided metrics snapshot states net debt to EBITDA stood at 0.8x as on June 30, 2026. It also shows ROCE at 16% versus 24% (down 8 percentage points). These ratios are useful for investors tracking balance sheet risk and operating efficiency, although the filing text provided does not expand further on the drivers behind the ROCE movement.

Compliance, availability of results, and key dates

The submission was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the outcome note also references Regulations 30 and 33. The Board meeting on July 27, 2026 commenced at 12:00 noon and concluded at 01:45 p.m. at the company’s registered office in Ahmedabad. The company said the unaudited results are available on its website under the Investor Relations section. The press release was signed by Gaurang Trivedi, Company Secretary and Compliance Officer, on July 27, 2026.

Corporate updates around the results period

The exchange disclosures also include an update dated July 22, 2026, about incorporation of a wholly owned subsidiary named “Epigral Advanced Materials Limited”. Separately, Epigral informed the exchanges about a conference call to discuss Q1 FY27 results on Monday, July 27, 2026 at 5:00 PM (IST). The invite listed company participants including Chairman and Managing Director Maulik Patel, Executive Director Kaushal Soparkar, CFO Rakesh Agrawal, and Milind Kotecha (Investor Relations and Strategy).

Key numbers at a glance

Why this update matters for specialty chemicals investors

The quarter’s disclosures show two things investors typically track in specialty chemicals: the ability to grow revenue in a volatile input environment, and the sensitivity of reported profits to costs and tax items. Epigral’s revenue rose year-on-year in the filing, and the company highlighted volume growth and better realizations. At the same time, the sharp rise in materials consumed and the absence of a one-time tax benefit from the prior year heavily influenced the year-on-year PAT comparison in the detailed numbers. The EBITDA margin staying near 25% suggests operating profitability remained relatively stable even as margins were lower than the year-ago period shown in the filing.

Conclusion

Epigral’s Q1 FY27 update for the quarter ended June 30, 2026 reported revenue around ₹705-709 crore, EBITDA near ₹180 crore, and PAT near ₹99 crore, with margins around 25%. The company’s filing points to higher material costs and a tax swing versus the year-ago quarter as key factors shaping the reported profit comparison. The unaudited results were approved by the Board on July 27, 2026 and have a limited review report from S R B C & CO LLP. Investors will also track any additional detail from the company’s scheduled conference call on July 27, 2026.